Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Obesity 3 Neoplasms 3 Sarcopenia 2 Prostatic Neoplasms 2 Polycystic Ovary Syndrome 2 Colorectal Neoplasms 2 Wound Infection 1 Weight Loss 1 Urinary Bladder Neoplasms 1 Surgical Wound Infection 1 Stomach Neoplasms 1 Smoldering Multiple Myeloma 1 Skin Neoplasms 1 Psoriasis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Postoperative Complications 1 Phagocyte Bactericidal Dysfunction 1 Pain 1 Overweight 1 Osteoarthritis 1 Olfaction Disorders 1 Non-alcoholic Fatty Liver Disease 1 Neuroma, Acoustic 1 Neoplasm, Residual 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Monoclonal Gammopathy of Undetermined Significance 1 Mandibular Neoplasms 1

Interventions

Carboplatin 177 Radiotherapy 139 Cisplatin 110 Pemetrexed 102 Docetaxel 93 Paclitaxel 92 Gemcitabine 78 Erlotinib Hydrochloride 73 Magnetic Resonance Spectroscopy 72 Radiosurgery 67 Bevacizumab 65 pembrolizumab 64 Etoposide 60 Blood Specimen Collection 60 durvalumab 53 Specimen Handling 48 Nivolumab 48 Surveys and Questionnaires 47 Drug Therapy 41 Standard of Care 35 Radiation 33 osimertinib 32 atezolizumab 32 Surgical Procedures, Operative 30 Topotecan 29 Irinotecan 29 Gefitinib 29 Educational Status 29 Early Intervention, Educational 29 Biopsy 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lung Neoplasms × Docosahexaenoic Acids × Clear all

NCT03936621 2019-05-07

Omega

British Columbia Cancer Agency

Phase 2 Unknown

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡